Antigenic characteristics and stability of microencapsulated Mycoplasma hyopneumoniae vaccine

C J Lee1, Y L Tzan

  • 1Department of Chemical Engineering, National Tsing Hua University, Hsinchu, Taiwan, ROC.

Insights

Enteric-coated microencapsulation significantly enhances the stability of Mycoplasma hyopneumoniae antigen (MHA). This oral vaccine delivery method protects MHA from heat, acidic conditions, and enzymatic degradation, improving its shelf life.

Area of Science:

  • Veterinary immunology
  • Biopharmaceutical formulation
  • Microbiology

Background:

  • Mycoplasma hyopneumoniae antigen (MHA) is crucial for developing oral vaccines.
  • Assessing MHA's in vitro stability is essential for vaccine efficacy.
  • Microencapsulation offers a potential strategy to improve antigen stability.

Purpose of the Study:

  • To evaluate the in vitro stability of MHA under various conditions (temperature, pH, trypsin).
  • To determine the effectiveness of enteric-coated microencapsulation using cellulose acetate phthalate (CAP) for MHA.
  • To assess the potential of microencapsulated MHA for oral vaccine applications.

Main Methods:

  • MHA was subjected to different temperatures (25-60°C), pH levels (acidic range), and trypsin digestion.
  • Microencapsulation of MHA was achieved using CAP to create enteric-coated microspheres.
  • Kinetic parameters (Arrhenius-type dependence, Michaelis-Menten model) were analyzed.

Main Results:

  • Enteric-coated MHA microspheres demonstrated superior thermal stability compared to unencapsulated MHA.
  • Microspheres effectively protected MHA from degradation in acidic environments (pH 1.2-4.0).
  • Microencapsulation significantly reduced trypsin degradation of MHA, indicated by lower K(A) and V(m) values.

Conclusions:

  • Enteric-coated microencapsulation with CAP enhances MHA stability against temperature, pH, and enzymatic challenges.
  • This formulation strategy prolongs the storage stability of MHA, retaining over 80% antigenicity for 95 days at 4°C.
  • Microencapsulated MHA shows promise for developing stable and effective oral vaccines against Mycoplasma hyopneumoniae.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...